
AMA and other medical associations are kicked out of CDC vaccine workgroups
The government told the organizations on Thursday via email that their experts are being disinvited from the workgroups that have been the backbone of the Advisory Committee on Immunization Practices.
The organizations include the American Medical Association, the American Academy of Pediatrics and the Infectious Diseases Society of America.
'I'm concerned and distressed,' said Dr. William Schaffner, a Vanderbilt University vaccine expert who for decades has been involved with ACIP and its workgroups.
He said the move will likely propel a confusing fragmentation of vaccine guidance, as patients may hear the government say one thing and hear their doctors say another.
One email said the organizations are 'special interest groups and therefore are expected to have a 'bias' based on their constituency and/or population that they represent.'
A federal health official on Friday confirmed the action, which was first reported by Bloomberg.
The decision was the latest development in what has become a saga involving the ACIP. The committee, created in 1964, makes recommendations to the Centers for Disease Control and Prevention on how vaccines that have been approved by the Food and Drug Administration should be used.
CDC directors have traditionally almost always approved those recommendations, which are widely heeded by doctors and greenlight insurance coverage for shots.
U.S. Health Secretary Robert F. Kennedy Jr. was a leading voice in the anti-vaccine movement before becoming the U.S. government's top health official, and in June abruptly fired the entire ACIP after accusing them of being too closely aligned with manufacturers. He handpicked replacements that include several vaccine skeptics.
The workgroups typically include committee members and experts from medical and scientific organizations. At workgroup meetings, members evaluate data from vaccine manufacturers and the CDC, and formulate vaccination recommendation proposals to be presented to the full committee.
The structure was created for several reasons, Schaffner said. The professional groups provide input about what might and might not be possible for doctors to implement. And it helped build respect and trust in ACIP recommendations, having the buy-in of respected medical organizations, he said.
Workgroup members are vetted for conflicts of interest, to make sure than no one who had, say, made money from working on a hepatitis vaccine was placed on the hepatitis committee, Schaffner noted.
Also disinvited from the groups were the American Academy of Family Physicians, the American College of Physicians, the American Geriatrics Society, the American Osteopathic Association, the National Medical Association and the National Foundation for Infectious Diseases.
In a joint statement Friday, the AMA and several of the other organizations said: 'To remove our deep medical expertise from this vital and once transparent process is irresponsible, dangerous to our nation's health, and will further undermine public and clinician trust in vaccines.'
They urged the administration to reconsider the move "so we can continue to feel confident in its vaccine recommendations for our patients.'
Some of the professional organizations have criticized Kennedy's changes to the ACIP, and three of the disinvited groups last month joined a lawsuit against the government over Kennedy's decision to stop recommending COVID-19 vaccines for most children and pregnant women.
In a social media post Friday, one of the Kennedy-appointed ACIP members — Retsef Levi — wrote that the working groups 'will engage experts from even broader set of disciplines!'
Levi, a business management professor, also wrote that working group membership 'will be based on merit & expertise — not membership in organizations proven to have (conflicts of interest) and radical & narrow view of public health!'
HHS officials have not said which people are going to be added to the ACIP workgroups.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Independent
an hour ago
- The Independent
World-first gonorrhoea vaccine rolled out across UK amid record levels of infection
England has launched a world-first gonorrhoea vaccination programme, aimed at curbing soaring infection rates and tackling the growing threat of antibiotic-resistant strains. The initiative comes after cases of the sexually transmitted infection (STI) in England reached a record 85,000 in 2023, the highest since records began in 1918. Available free of charge from Monday at sexual health clinics, the jab is being offered to those at highest risk. This includes gay and bisexual men with a recent history of multiple sexual partners or a bacterial STI. The vaccine, an existing jab known as 4CMenB, is currently used to protect against meningococcal B disease, which can cause meningitis and sepsis. It is used in the routine childhood programme and given to babies at eight weeks, 16 weeks and one year. Officials anticipate the programme will save the NHS £7.9 million over the next decade. The programme could prevent up to 100,000 cases of gonorrhoea, according to doctors. The STI disproportionately impacts specific communities, such as those in deprived areas, people of black Caribbean ethnicity, and gay, bisexual and other men who have sex with men, according to the Joint Committee on Vaccination and Immunisation (JCVI). Patients getting the gonorrhoea vaccine will also be offered jabs for mpox, human papillomavirus (HPV), and hepatitis A and B at their appointment. 'Rolling out this world-leading gonorrhoea vaccination programme in sexual health clinics in England represents a major breakthrough in preventing an infection that has reached record levels,' Ashley Dalton, the minister for public health and prevention, said. 'This government's world-first vaccination programme will help turn the tide on infections, as well as tackling head-on the growing threat of antibiotic resistance. 'I strongly encourage anyone who is eligible to come forward for vaccination, to protect not only yourselves but also your sexual partners.'


The Independent
an hour ago
- The Independent
Warning issued to patients who stop using weight-loss jabs
Health chiefs have raised concerns about patients regaining weight after stopping popular weight-loss drugs such as Wegovy and Mounjaro, calling for robust support to prevent them from piling on the pounds again. The National Institute for Health and Care Excellence (Nice), the UK's health watchdog, highlighted research indicating that many individuals regain weight if not adequately supported after ceasing treatment. Nice stressed that those coming off the drugs should be offered "structured advice and follow-up support" to mitigate weight gain. This guidance specifically applies to individuals receiving these treatments through the NHS. However, an estimated 1.5 million people in the UK are currently using weight-loss injections, with the vast majority paying privately. These individuals will not be eligible for NHS support once their treatment concludes. Over the next three years, approximately 240,000 people deemed to have the "greatest need" are anticipated to receive Mounjaro, also known as tirzepatide, via the NHS. The new 'quality standard' from Nice says that NHS patients should be monitored for at least a year after they complete treatment, and extra support should be offered if needed. It emphasises building 'long-term behavioural habits, use self-monitoring tools, and draw on wider support – from online communities to family-led interventions and local activities'. This standard, a type of guidance for the health services in England and Wales, sets out expectations for health providers including how they should support patients. 'Successful weight management doesn't end when medication stops or when someone completes a behavioural programme,' said Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice. 'We know that the transition period after treatment is crucial, and people need structured support to maintain the positive changes they've made. 'This new standard makes sure services provide that vital continuity of care, and it supports the NHS 10 Year Plan to shift from a 'sickness service' to a genuine health service focused on prevention.' Dr Rebecca Payne, chair of Nice's Quality Standards Advisory Committee, added: 'Weight management is a long-term journey, not a short-term fix. 'The evidence is clear that advice and support for maintaining weight after stopping medicines or completing behavioural interventions can help prevent weight regain and enable people to experience lasting benefits. 'We've seen excellent examples of services that already provide comprehensive discharge planning and ongoing support. 'This quality standard will help ensure all healthcare providers adopt these best practices, giving every person the best chance of maintaining their weight management success over the long term. 'This standard ensures healthcare services are equipped to provide that essential ongoing support.' Commenting, Henry Gregg, chief executive of the National Pharmacy Association, said: ' Pharmacies take their responsibilities seriously to provide full wrap around support to patients trying to achieve a healthy weight. 'We know that although medication can be effective in speeding up weight loss in some people, it is not a silver bullet and patients need to make long term lifestyle changes to make their weight loss sustainable. 'The current NHS roll out of weight loss treatment is very small, with only a handful of patients receiving it and it will continue to be the case that the vast majority of eligible patients will be seen by their pharmacy.' Professor Kamila Hawthorne, chairwoman of the Royal College of GPs, said: 'There is no one-size-fits-all approach to tackling obesity – what works for one patient will likely not work for another and, as with any medication, weight-loss drugs do not come without risk. 'It's also the case that patients will likely need support to sustain their weight loss once they stop taking the medication. As such, this is important and sensible guidance from Nice. 'As a college, we've been clear that whilst weight loss medications have significant potential benefits for patients who are struggling to lose weight, they mustn't be seen as a 'silver bullet' and ensuring access to sufficient 'wraparound' services – particularly for when patients come off their medication – will be key to optimal health outcomes.'


Reuters
an hour ago
- Reuters
Dialysis firm FMC's earnings miss market view, hit by severe flu season in US
Aug 5 (Reuters) - Dialysis specialist Fresenius Medical Care ( opens new tab missed analysts' earnings forecasts on Tuesday, after a severe flu season in the U.S. led to higher mortality among patients and a greater number of missed treatments in the first months of 2025. FMC, which makes the bulk of its sales in the U.S. and employs most of its staff there, however was "encouraged by the strong and accelerating momentum in patient referrals" that had continued in the second quarter, CEO Helen Giza said in a statement. But the positive development in patient inflow was offset by a higher than expected outflow due to higher mortality rates in the U.S. following the severe flu season, she added. That has impacted treatment numbers for the second quarter and for the remainder of the year, FMC said. The world's largest dialysis provider said its adjusted operating income grew 9% to 476 million euros ($550.2 million) in the second quarter, but missed analysts' average estimate of 492 million euros in a company-provided consensus. Its shares were down around 3% in early Frankfurt trade. U.S. same market treatment growth was flat year-on-year, as a rise in newly started treatments partially offset patient outflow. FMC has guided for same market treatment growth of more than 0.5% in the U.S. in 2025. Quarterly revenue grew 5% in constant currency terms to 4.79 billion euros, slightly above analysts' expectations, helped by savings of 58 million euros attributable to the group's FME25 transformation program. The German group confirmed its full-year guidance, as it expects "to realize further significant operational and financial improvements" in the second half of the year, Giza said. It also said it would initiate the first tranche of its 1 billion euro share buyback programme in August. ($1 = 0.8651 euros)